Prostate Specific Membrane Antigen (PSMA) Clinical Research Trial

About the Study

  • PSMA (or prostate specific membrane antigen) is a protein found on most prostate cancers. 68Ga-PSMA-11, also known as 68Ga-PSMA HBED-CC, is an imaging agent that binds to prostate cancer cells and can be imaged using a PET (Positron Emission Tomography) scanner. In this study, we will be testing Gallium-68 PSMA PET imaging.    
  • A PET scan uses a special camera to detect energy given off from radioactive material to make detailed pictures of areas where the Ga-68 accumulates in the body. When combined with an MRI or CT scan, the PET scan helps to more accurately map the location of where in the body the radioactive material has collected.
  • The researchers are conducting this study to help us determine the ability of 68Ga-PSMA-11 to detect the presence of prostate cancer metastasis.
  • This is a research study. 68Ga-PSMA-11 is not approved by the Food and Drug Administration (FDA).

Eligibility

Inclusion

  • Male, age ≥ 18
  • Histopathologically proven prostate adenocarcinoma.
  • Concern for metastatic disease in one of the following settings:
    • Initial stating with intermediate to high risk prostate cancer
    • Biochemical recurrence after initial therapy

Exclusion

  • Patients unlikely to comply with study procedures, restrictions and requirements and judged by the investigator to be unsuitable for study participation.

Screening (must be completed within 90 days of Imaging Visit)

  • PSA - Prostate Specific Antigen

Website Resources

Contact Info